SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Biomea Fusion, Inc.
Date: Aug. 12, 2025 · CIK: 0001840439 · Accession: 0000000000-25-008473

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-289262

Date
August 12, 2025
Author
Division of
Form
UPLOAD
Company
Biomea Fusion, Inc.

Letter

Re: Biomea Fusion, Inc. Registration Statement on Form S-3 Filed August 5, 2025 File No. 333-289262 Dear Dr. Michael J.M. Hitchcock:

August 12, 2025

Dr. Michael J.M. Hitchcock Interim Chief Executive Officer and Director Biomea Fusion, Inc. 1599 Industrial Road San Carlos, CA 94070

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Alicia M. Tschirhart, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 August 12, 2025

Dr. Michael J.M. Hitchcock
Interim Chief Executive Officer and Director
Biomea Fusion, Inc.
1599 Industrial Road
San Carlos, CA 94070

 Re: Biomea Fusion, Inc.
 Registration Statement on Form S-3
 Filed August 5, 2025
 File No. 333-289262
Dear Dr. Michael J.M. Hitchcock:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Daniel Crawford at 202-551-7767 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Alicia M. Tschirhart, Esq.
</TEXT>
</DOCUMENT>